drugset / Trial / NCT07522099
Chinese Adults With Kidney Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Timeline
- Start
- 2026-05-21
- Primary completion
- 2028-07-10
- Completion
- 2029-01-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPI-1007 | Small interfering RNA (siRNA) | — | — |
| Subject | Telitacicept | Protein / enzyme biologic | — | — |